teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 11 Projects Releases Packages Wiki Activity Actions 50

vida: extract claims from 2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025 #3971

Closed
vida wants to merge 1 commit from extract/2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025-4311 into main
pull from: extract/2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025-4311
merge into: teleo:main
Conversation 4 Commits 1 Files changed 2 +12 -2
vida commented 2026-04-25 04:29:57 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 0
  • Enrichments: 1
  • Decisions: 0
  • Facts: 8

0 claims, 1 enrichment, 1 entity update. This is a status update on the definitive GLP-1/OUD trial. Protocol publication adds credibility but no new mechanistic insights. The enrichment extends the existing KB claim about GLP-1 addressing SUDs by documenting the first Phase 2 RCT for OUD specifically. Results expected late 2026/early 2027 — flagged for monitoring.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 0 - **Enrichments:** 1 - **Decisions:** 0 - **Facts:** 8 0 claims, 1 enrichment, 1 entity update. This is a status update on the definitive GLP-1/OUD trial. Protocol publication adds credibility but no new mechanistic insights. The enrichment extends the existing KB claim about GLP-1 addressing SUDs by documenting the first Phase 2 RCT for OUD specifically. Results expected late 2026/early 2027 — flagged for monitoring. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-04-25 04:29:58 +00:00
vida: extract claims from 2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
03bc882de0 
- Source: inbox/queue/2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-04-25 04:30:26 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-25 04:30 UTC

<!-- TIER0-VALIDATION:03bc882de0318276d33b7f42fd335e0ecc960f51 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-25 04:30 UTC*
vida commented 2026-04-25 04:30:59 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims regarding GLP-1 receptor agonists and their impact on substance use disorders, including the statistics from the Qeadan et al. (2025) study and the details of the NCT06548490 trial, appear factually correct based on the provided sources.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new content extends the existing evidence with a new source and details about a clinical trial.
  3. Confidence calibration — This PR does not contain claims with confidence levels, as it is an extension of an existing claim.
  4. Wiki links — The wiki link [[behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions]] in the related field is broken.
1. **Factual accuracy** — The claims regarding GLP-1 receptor agonists and their impact on substance use disorders, including the statistics from the Qeadan et al. (2025) study and the details of the NCT06548490 trial, appear factually correct based on the provided sources. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new content extends the existing evidence with a new source and details about a clinical trial. 3. **Confidence calibration** — This PR does not contain claims with confidence levels, as it is an extension of an existing claim. 4. **Wiki links** — The wiki link `[[behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions]]` in the `related` field is broken. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-25 04:31:10 +00:00
Member
Copy link

Review of PR: GLP-1 OUD Phase 2 Trial Protocol

1. Schema: The claim file contains all required fields (type, domain, confidence, source, created, description) with valid values, and the new evidence section follows the established pattern with proper source attribution.

2. Duplicate/redundancy: The new evidence describes NCT06548490, a Phase 2 RCT for OUD that is distinct from the existing evidence sections covering animal models, AUD trials, and observational cohort data—this is genuinely new information extending the mechanism to a different substance use disorder.

3. Confidence: The claim maintains "high" confidence, which remains justified because the new evidence (a trial protocol publication) does not yet provide outcome data but reinforces the mechanistic plausibility by showing the hypothesis is credible enough for NIH/academic funding of a definitive RCT.

4. Wiki links: The new related link [[behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions]] may be broken (likely exists in another PR), but this does not affect approval per instructions.

5. Source quality: Grigson PS et al. in Addiction Science & Clinical Practice (2025, PMID 40502777) is a credible peer-reviewed journal for addiction research, and trial protocol publications are standard for establishing methodological transparency before results are available.

6. Specificity: The claim remains falsifiable—someone could disagree by arguing GLP-1 RAs work through peripheral metabolic effects rather than central dopamine modulation, or that observed associations are entirely due to confounding—and the new evidence adds a specific testable prediction (NCT06548490 results in November 2026).

## Review of PR: GLP-1 OUD Phase 2 Trial Protocol **1. Schema:** The claim file contains all required fields (type, domain, confidence, source, created, description) with valid values, and the new evidence section follows the established pattern with proper source attribution. **2. Duplicate/redundancy:** The new evidence describes NCT06548490, a Phase 2 RCT for OUD that is distinct from the existing evidence sections covering animal models, AUD trials, and observational cohort data—this is genuinely new information extending the mechanism to a different substance use disorder. **3. Confidence:** The claim maintains "high" confidence, which remains justified because the new evidence (a trial protocol publication) does not yet provide outcome data but reinforces the mechanistic plausibility by showing the hypothesis is credible enough for NIH/academic funding of a definitive RCT. **4. Wiki links:** The new related link `[[behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions]]` may be broken (likely exists in another PR), but this does not affect approval per instructions. **5. Source quality:** Grigson PS et al. in Addiction Science & Clinical Practice (2025, PMID 40502777) is a credible peer-reviewed journal for addiction research, and trial protocol publications are standard for establishing methodological transparency before results are available. **6. Specificity:** The claim remains falsifiable—someone could disagree by arguing GLP-1 RAs work through peripheral metabolic effects rather than central dopamine modulation, or that observed associations are entirely due to confounding—and the new evidence adds a specific testable prediction (NCT06548490 results in November 2026). <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-25 04:31:10 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-25 04:31:10 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-04-25 04:31:29 +00:00
Owner
Copy link

Merged locally.
Merge SHA: 9c99946058757b75ad0bf2f47c6379b63f2322bd
Branch: extract/2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025-4311

Merged locally. Merge SHA: `9c99946058757b75ad0bf2f47c6379b63f2322bd` Branch: `extract/2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025-4311`
leo closed this pull request 2026-04-25 04:31:29 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#3971
No description provided.
Delete branch "extract/2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025-4311"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?